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Résumé
Objectif: L’objectif primaire était de comparer la réponse érythropoïétique de
deux doses d’érythropoïétine humaine recombinante (EPO) exprimée par la
variation moyenne des réticulocytes et de l’hémoglobine durant le séjour aux
soins intensifs. Devis: étude prospective, ouverte, multicentrique. Patients : 58
patients hospitalisés aux unités de soins intensifs chirurgicaux et/ou médicaux
de trois centres hospitaliers de soins généraux spécialisés et ultraspécialisés
québécois entre juillet 2003 et décembre 2004. Intervention : les patients inclus
dans l’étude recevaient soit EPO 40 000 unités sous-cutanée J fois pat semaine
(groupe A) ou EPO 40 000 unités sous-cutané 2 fois par semaine (groupe B),
pour 4 doses maximum durant le séjour aux soins intensifs. Les patients ont été
recrutés successivement : les 30 premiers patients correspondant au groupe A,
les patients suivants correspondant au groupe B. Si la condition clinique du
patient le requérait, une transfusion pouvait être administrée si l’hémoglobine
était inférieure à 70 g/L ou si l’hémoglobine était inférieure à 90 g/L en présence
de syndrome coronarien aigu. Aucune transfusion ne devait être administrée
uniquement sur une valeur d’hémoglobine. Résultats : 30 patients ont été
recrutés dans le groupe A et 28 patients dans le groupe B. Aucune différence
statistiquement significative entre les deux groupes ne fut observée au niveau
de la variation quotidienne des réticulocytes ou de l’hémoglobine. Conclusion
une dose d’EPO supérieure à 40 000 unités par semaine ne permet pas
d’obtenir une stimulation des réticulocytes ou une production d’hémoglobine
plus rapide, plus élevée ou plus soutenue chez les patients hospitalisés aux
soins intensifs.
Mots-clés: érythropoïétine humaine recombinante, réticulocytes, hémoglobine,
anémie, transfusion sanguine, soins intensifs, pratique transfusionnelle.
VAbstract
Objective: The primary objective was to compare response of erythropoiesis of
2 doses cf recombinant human erythropoietin f EPO) expressed by the average
variation cf reticulocytes count and hemoglobin during the stay in intensive care.
Desing : prospective, multiple center, open study. Patients: 58 patients
hospitalized in the multidisciplinary intensive care units (ICU) cf 3 hospitals in
Québec, between July 2003 and December 2004. Intervention: the patients
included in the study received 40 000 units cf EPO weekly by subcutaneous
injection (group A) or 40 000 units cf EPO twice a week (group B), for a
maximum cf 4 doses during the stay in the ICU. The patients were recruited
successively: the first 30 patients corresponding te the group A, the follcwing
patients ccrresponding te the group B. If the clinical condition cf the patient
required it, a transfusion could be administered with hemoglobin < 70 g/L et
hemoglobin < 90 gIL in the presence of acute coronary syndrome. No
transfusion based cnly on a single value cf hemoglobin. Results: 30 patients
were encolled in the group A and 28 patients in the group B. Ne statistically
significant difference between the two groups was observed for the daily
variation of réticulocytes or hemoglobin. Conclusion: a dose cf EPO > 40 000
units weekly does net provide a higher or a more sustained stimulation of
reticulocytes or hemoglobin production in ICU patients.
Key words : recombinant human erythropoietin, reticulocytes, hemoglobin,
anemia, blood transfusion, critical illness, transfusion practice.
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INTRODUCTION
Depuis quelques années, une attention particulière est portée afin de diminuer
le nombre de transfusions chez les patients aux soins intensifs.1 Les équipes
traitantes ont été sensibilisées aux effets délétères pouvant survenir à la suite
d’une transfusion de globules rouges.1’2 Traditionnellement, l’administration de
culots globulaires chez les patients aux soins intensifs était courante afin de
maintenir une concentration d’hémoglobine au-dessus de 100 g/L.3 Une étude
importante menée au Canada et publiée en 1999 amena toutefois les équipes
traitantes à repenser leur pratique transfusionneHe.1 En effet, cette étude
démontrait qu’une approche transfusionnelle libérale n’était pas plus efficace
qu’une stratégie transfusionnelle restrictive, voire même néfaste chez les
patients moins âgés et les patients moins sévèrement malades.1’4 La
transfusion de globules rouges est théoriquement administrée afin d’augmenter
les concentrations d’hémoglobine dans le sang et ainsi optimiser la livraison
d’oxygène aux tissus. Toutefois, il semble que l’hémoglobine provenant du sang
transfusé
ne soit pas aussi performante que l’hémoglobine formée par les
patients.5 La livraison tissulaire en oxygène augmente effectivement suite à la
transfusion mais la captation tissulaire en oxygène serait altérée, diminuant
ainsi le but ultime de la transfusion.5 À cela s’ajoutent les complications reliées à
la transfusion telles que la formation de microthromboses, la fièvre et
l’émergence de problèmes respiratoires ou TRALI (Transfusion Related Acute
Lung lnjury).2
Les réserves de sang sont limitées et coûteuses. Afin d’assurer une utilisation
judicieuse des produits sanguins, des programmes de conservation du sang
doivent être instaurés dans les centres hospitaliers par l’intermédiaire d’un
comité de médecine transfusionnelle. Les stratégies développées pour
restreindre la transfusion de globules rouges devraient d’abord s’intégrer à une
pratique transfusionnelle restrictive basée sur l’état clinique des patients et non
pas seulement sur une valeur d’hémoglobine. Diminuer le volume des tubes de
2prélèvement et restreindre les analyses de laboratoires font partie des
stratégies pour diminuer les besoins transfusionnels. L’utilisation
d’érythropoïétine humaine recombinante (EPO) afin de stimuler l’érythropoïèse
pourrait également être une alternative à la transfusion qui favoriserait la
production d’hémoglobine performante sans les effets néfastes de la
transfusion.
Normalement, les concentrations d’EPO endogène augmentent rapidement en
présence d’anémie. Toutefois, une réponse anormale est souvent observée
lors d’états inflammatoires. Les médiateurs de l’inflammation inhiberaient la
production d’EPO, favoriseraient la dégradation des globules rouges et
augmenteraient la séquestration du fer nécessaire à l’érythropoïèse. Bien que
les pertes sanguines soient souvent importantes aux soins intensifs, l’anémie
observée chez ces patients serait principalement de nature inflammatoire.
Plusieurs patients ne présentant pas de saignements auront une baisse
d’hémoglobine constante durant le séjour aux soins intensifs. L’utilisation de
l’EPO précocément chez ces patients pourrait permettre la stimulation de
l’érythropoÏèse malgré l’inflammation.
Pajoumand et coil. proposaient récemment des recommandations pour
l’utilisation de l’EPO chez les patients aux soins intensifs.6 À la lumière des
études publiées, les auteurs concluaient que 40 000 unités d’EPO une fois par
semaine pouvaient être utilisées comme alternative à la transfusion mais que la
dose optimale n’était pas clairement établie.6 Toutefois, étant donné le coût
élevé de l’EPO, nous croyons qu’elle devrait être utilisée conjointement avec
une approche transfusionnelle restrictive telle que celle proposée dans l’étude
TRICC1 (Transfusion Requirement in Critical Care). Il ne serait pas judicieux
d’ajouter une thérapie coûteuse visant à diminuer les transfusions tout en
transfusant de façon libérale [VOIR ARTICLE IJ.
3REVUE DE LITTÉRATURE
Utilisation de l’EPO aux sobts intenstfs
Quelques études ont démontré qu’il était possible d’obtenir une stimulation
rapide de l’érythropoÏèse chez les patients aux soins intensifs en administrant
de hautes doses d’EPO.71° Une revue systématique de la littérature publiée
entre 1990 et 2001 recensait quatre études évaluant l’administration d’EPO
dans ce contexte [VOIR ARTICLE 111.11 Parmi elles, une seule étude (EPO-1)
mesurait l’impact clinique de l’EPO sur les besoins transfusionnels.1° L’étude
EPO-1, effectuée chez 160 patients, démontrait une diminution d’environ 50%
des besoins transfusionnels cumulatifs chez les patients recevant l’EPO par
rapport au groupe placebo. Les doses d’EPO correspondaient alors à environ
100 000 unités pour les 5 premiers jours, suivies de 60 000 unités par semaine
pour un patient de 70 kg. Toutefois, les nombreux critères d’exclusion de cette
étude limitaient l’utilisation d’EPO dans un contexte de soins intensifs. D’autres
études étaient donc nécessaires avant d’utiliser l’EPO chez les patients aux
soins intensifs [VOIR ARTICLE ll-CONCLUSIONJ. En 2002, une étude de
grande envergure (EPO-2) fut pubHée.12
L’étude EPO-2 était une étude prospective, à double-insu et contrôlée par
placebo avec répartition aléatoire des sujets, mesurant l’impact de
l’administration d’EPO sur les besoins transfusionnels des patients aux soins
intensifs.12 Elle fut menée dans 65 unités de soins intensifs médicaux et/ou
chirurgicaux. Les patients étaient inclus lors du troisième jour d’hospitalisation
aux soins intensifs s’ils étaient âgés de plus de 18 ans en présence d’une valeur
d’hématocrite inférieure à 38 ¾. Les patients étaient exclus s’ils présentaient
des antécédants de convulsions, un saignement gastro-intestinal actif, une
hypertension non contrôlée, un syndrome coronarien aigu, s’ils étaient dialysés
chroniquement ou déjà sous EPO. L’objectif principal était de comparer le
pourcentage de patients dans chaque groupe ayant reçu au moins une
4transfusion de globules rouges du jour 1 au jour 28 de l’étude. Le nombre
cumulatif de transfusions pour chaque groupe ainsi que le taux de mortalité à 28
jours furent également mesurés.
Durant le séjour aux soins intensifs, les patients recevaient 40 000 unités d’EPO
ou un placebo sous-cutané une fois par semaine pour un maximum de quatre
doses. L’administration de la médication était interrompue temporairement
lorsque l’hématocrite excédait 38 %. Tous les patients recevaient également un
supplément de fer oral ou parentéral correspondant à au moins 150 mg de fer
élémentaire par jour.
Au total, 1302 patients ont été inclus dans l’étude soit 650 patients dans le
groupe recevant l’EPO et 652 patients dans le groupe placebo. Les
caractéristiques des deux groupes au moment de la répartition aléatoire étaient
comparables au niveau de l’âge, de l’hémoglobine, du taux d’érythrocytes et au
niveau de la sévérité de la maladie.
Plus de la moitié des patients du groupe placebo (60,4%) ont reçu au moins une
transfusion entre le jour 1 et le jour 28 comparativement à 50,5% des patients
recevant l’EPO (394 patients vs 328 patients; respectivement, p < 0.001). Une
réduction de 19% du nombre cumulatif de culots de globules rouges transfusés
dans le groupe recevant l’EPO a également été observée comparativement au
groupe placebo (1590 culots vs 1963 culots; respectivement). Par contre,
aucune différence statistiquement significative ne fut observée entre les deux
groupes au niveau de la mortalité, de la durée de séjour aux soins intensifs ou
des besoins en ventilation mécanique. L’incidence d’effets indésirables pouvant
être attribuables à l’EPO était comparable dans les deux groupes.
L’étude EPO-1 ne précisait pas de critères transfusionnels, la décision de
transfuser étant laissée à la discrétion de l’équipe traitante. Cette faiblesse fut
corrigée dans l’étude EPO-2, pour laquelle un seuil transfusionnel était établi
5aucune transfusion en présence d’une hémoglobine supérieure à 90 gIL ou
d’une valeur d’hématocrite supérieure à 27%, à moins d’une condition aigué le
requérant. À partir de ce seuil transfusionnel, les patients étaient transfusés à la
discrétion de l’équipe traitante.
Étant donné les risques et les limites associés à la transfusion de globules
rouges, il apparaît particulièrement important de réduire les besoins
transfusionnels durant le séjour aux soins intensifs. Par conséquent, il aurait été
intéressant de connaître l’impact sur les besoins transfusionnels non seulement
à 28 jours mais également durant le séjour aux soins intensifs. Les bénéfices
observés dans l’étude EPO-2 sont modestes par rapport à ceux observés dans
l’étude EPO-1. Cette différence pourrait en partie s’expliquer par la dose
beaucoup plus faible utilisée dans l’étude EPO-2. Le régime thérapeutique
optimal d’EPO reste donc à déterminer.
Métabolisme du fer citez tes patients aux soins intensifs
L’augmentation de l’érythropoïèse induite par l’administration d’EPO augmente
les besoins en fer.13 li est donc essentiel d’administrer un supplément de fer aux
patients qui reçoivent de l’EPO afin d’optimiser la réponse et de prévenir une
carence fonctionnelle en fer. L’administration de fer dans le contexte des soins
intensifs représente toutefois un véritable défi. Les suppléments de fer peuvent
être administrés par voie orale, intramusculaire ou intraveineuse.
L’administration de fer par voie intramusculaire n’apparaît pas idéale étant
donné la grande variabilité de sa biodisponibilité et la proportion non
négligeable de malades anticoagulés à risque d’hématome. L’administration de
fer intraveineux est discutable chez cette population de patients puisqu’il existe
un risque théorique de promouvoir la croissance bactérienne lorsque le fer est
administré par cette voie.14 La voie orale semble donc être à privilégier dans ce
contexte. Toutefois, l’utilisation du fer par voie orale aux soins intensifs, est
généralement limitée par sa faible biodisponibilité et les conditions médicales
6qui rendent le tube digestif non fonctionnel. La dose de fer adéquate est
également difficile à déterminer puisque le contexte inflammatoire modifie
considérablement le métabolisme du fer, ne permettant pas un suivi approprié
des paramètres habituels.15 [VOIR ARTICLE III].
OBJECTIFS
Notre étude a été élaborée pour évaluer si l’administration d’une dose d’EPO
supérieure à 40 000 unités par semaine, conjointement avec un seuil
transfusionnel restrictif, stimule d’avantage l’érythropoïèse des patients aux
soins intensifs. L’objectif principal était de comparer la stimulation de
l’érythropoïèse de deux doses d’EPO chez les patients sévèrement malades
aux soins intensifs. Les paramètres de l’érythropoïèse mesurés étaient la
variation moyenne de l’hémoglobine et des réticulocytes durant le séjour aux
soins intensifs. Cette étude visait à évaluer si une augmentation des doses
d’EPO permettait une stimulation accrue de l’érythropoïèse spécifiquement
durant le séjour aux soins intensifs.
MÉTHODOLOGIE
Cette étude ouverte et prospective a été menée dans les unités de soins
intensifs de la Cité de la Santé de Lavai, de l’Hôpital du Sacré-Coeur de
Montréal et de l’institut de Cardiologie de Montréal entre juillet 2003 et
décembre 2004. L’étude était de nature exploratoire, la taille des échantillons
ayant été déterminée par des considérations économiques et de faisabilité. Les
30 premiers patients (groupe A) inclus à l’étude selon les critères d’inclusion et
d’exclusion recevaient 40 000 unités d’EPO une fois par semaine pour un
maximum de 4 doses. Les 30 patients suivants (groupe B) devaient recevoir 40
000 unités d’EPO deux fois par semaine pour un maximum de 4 doses. Les
critères transfusionnels utilisés étaient aucune transfusion basée uniquement
) sur une valeur d’hémoglobine. Si la condition clinique du patient le requérait, ii
7pouvait être transfusé si L’hémoglobine < 70 gIL ou hémoglobine < 90 g/L en
présence de syndrome coronarien aigu. [Voir l’ARTICLE IV pour une
description détaillée de la méthodologie].
RÉSULTATS
Au total, 58 patients ont été inclus à l’étude dont 30 dans le groupe A et 28 dans
le groupe B. Les caractéristiques de base des patients étaient généralement
comparables entre les deux groupes. Le score APACHE Il moyen était environ
de 21 pour les deux groupes. Au moment de l’inclusion à l’étude, près de la
moitié des patients recevaient un vasopresseur et la majorité des patients
étaient ventilés mécaniquement. La ferritine élevée et la saturation de la
transferrine abaissée dans les deux groupes étaient caractéristiques d’un état
inflammatoire.
Aucune différence statistiquement significative entre les deux groupes ne fut
observée au niveau des réticulocytes. Une augmentation significative des
réticulocytes a été observée dans chacun des groupes par rapport aux valeurs
de base. Aucune différence significative ne fut observée entre les deux groupes
au niveau de la variation quotidienne des concentrations d’hémoglobine durant
le séjour aux soins intensifs. Les seuils transfusionnels ont globalement été
respectés : l’hémoglobine moyenne pré-transfusion était de 72 ± 9 g/L dans le
groupe A et de 67 ± 6 g/L dans le groupe B. [Une description plus détaillée
des résultats est présentée dans l’article IV].
DISCUSSION
Notre étude démontre qu’il n’y a pas d’avantage à utiliser une dose d’EPO
supérieure à 40 000 unités par semaine au niveau de la production des
réticulocytes. Dans une étude précédante, Corwin et cdl. avaient utilisé une
dose beaucoup plus élevée et démontré une réduction de près 50% des
$besoins transfusionnels chez les patients recevant l’EPO comparativement au
placebo.1° Les résultats plus modestes observés dans la seconde étude4,
imposaient d’étudier si un effet maximal était atteint avec une dose de 40 000
unités d’EPO une fois par semaine.
Dans notre étude, aucune différence ne fut observée entre les deux groupes au
niveau de la variation quotidienne de l’hémoglobine durant le séjour aux soins
intensifs. Notre étude est la première à évaluer l’effet de l’EPO conjointement
avec une approche transfusionnelle restrictive telle qu’utilisée dans l’étude
TRICC1. La valeur moyenne de l’hémoglobine pré-transfusion observée dans
l’étude de Corwin et coU. Était de 86 g/L. Nos critères transfusionnels plus
restrictifs ont permis d’obtenir une hémoglobine moyenne pré-transfusion de 72
g/L pour le groupe A et de 67 g/L pour le groupe B. On observe dans notre
étude une stabilisation dés concentrations d’hémoglobine durant 28 jours aux
soins intensifs. Bien qu’un seuil transfusionnel moyen à 72 gJL ait été appliqué
pour le groupe A, la concentration moyenne de l’hémoglobine durant le séjour
aux soins intensifs se situait près de 90 g/L. Cette augmentation pourrait être
secondaire à l’administration d’EPO. [Voir l’article IV pour une discussion
plus détaillée).
L’utilisation de l’EPO à hautes doses dans le contexte des soins intensifs était
peu étudiée et requérait un suivi des effets indésirables. Les effets secondaires
de l’EPO ont principalement été rapportés chez les patients insuffisants rénaux
ambulatoires. Parmi ces effets secondaires, l’hypertension (rapporté chez 24%
des patients insuffisants rénaux) et les troubles thromboemboliques (0,04
événements par patient-année) étaient les plus préoccupants. Le faible nombre
de patients dans notre étude ne permettait certainement pas de faire émerger
de façon claire ces effets secondaires. Toutefois, un comité de surveillance
indépendant avait été mis en place dans le cas où le contexte des soins
intensifs aurait fortement augmenté l’incidence de ces événements. [Les effets
9secondaires pouvant être attribuables à I’EPO sont rapportés dans
l’ARTILE IV].
CONCLUSION
Une dose d’EPO supérieure à 40 000 unités par semaine ne permet pas
d’obtenir une stimulation des réticulocytes ou une production d’hémoglobine
plus rapide, plus élevée ou plus soutenue chez les patients hospitalisés aux
soins intensifs.
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0 TotheEditor:
The recommendations provided by Pajoumand et al in their article recently
published in The Annals ‘ are interesting. However, these recommendations on
the use of EPO in critically BI patients should be integrated to a blood
conservation strategy. As reported in the ABC study2, the amount of blood loss
through blood sampling in the ICU is considerable, averaging 41 mL per day.
Therefore, sparing mechanisms to reduce blood draws should be developed in
the ICU before widespread utilisation of EPO. Non pharmacological alternatives
such as limiting blood collection, using smaller collecting tubes and restrictive
transfusion thresholds are among the strategies.
lndeed, we strongly believe that a restrictive transfusion approach is an
important step to implement a blood conservation strategy in critically iII
patients. The use of EPO without a restrictive transfusion approach would flot
be efficient. In our ICU, the transfusion medicine committee developed a tool to
ensure an appropriate use of red blood ceils transfusions. The tool is a
prescription with printed recommendations for blood products administration.
Among others, these recommendations specify that the prescription of red blood
cells transfusion should be based on the clinical condition of the patient rather
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than on a single hematocrit or hemoglobin value. We simply ask to the medical
team to prescribe blood products on that tool and to justify the reason of
transfusion. We assume that this exercice will educate, change transfusion
practice and avoid unnecessary blood transfusion.
A review of the litterature concerning the role of EPO in critically III patients was
also published two years ago in The Annals . When we revised this topic, the
EPO-2 study conducted by Dr Corwin and colleagues4 had not been published
yet. We support Dr Pajoumand et al. conclusion that optimal EPO dosage
remains to be determined. It seems that higher doses of EPO couid provide a
higher erythropoiesis response during the ICU stay. More important, additional
studies combining the use of EPO with a restrictive transfusion approach such
as proposed in the TRICC trial needed.
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ABSTRACT
OBJECTIVE: b review the literature concerning the role of recombinant human
erythropoietin (rHuEPO) in reducing the need for transfusion in intensive care
patients.
DATA SOURCES: Articles were obtained through searches cf MEDLINE
database (1990 to June 2001) using the key words erythropoietin, epoetin alfa,
anemia, reticulocytes, hemoglobin, critical care, intensive care, critical illness
and blood transfusion. Additional references were found in the bibliographies of
the articles cited. The Cochrane Iibrary was also consulted.
STUDY SELECTION AND DATA EXTRACTION: Controlled, prospective,
randomized studies on the use of rHuEPO in critically iII aduits were selected.
DATA SYNTHESIS: Anemia is a common complication in intensive care
patients. t is caused, in part, by abnormally low levels of endogenous
erythropoietin and is seen mainly in patients with sepsis and multiple organ
dysfunction syndrome, in whom inflammation mediator levels are often elevated.
High doses of rHuEPO produce a rapid response in these patients, despite
elevated cytokine levels. There have been three studies on rHuEPO
administration in intensive care and one study in acutely burned patients. Only
two of these studies looked at the impact of rHuEPO administration on the need
for transfusion.
CONCLUSION: In summary, few randomized controlled trials explore the role of
b
rHuEPO in the intensive care. OnIy one was a large randomized clinical trial but
presents many limitations. Future outcome and safety studies comparing
Article II-14
rHuEPO vs placebo must include clinical end points such as end organ
morbidity, mortality, transfusion requirements and pharmacoeconomic analysis.
rHuEPO appears to provide an erythropoietic response. Optimal dosage and the
real impact of rHuEPO on the need for transfusion in intensive care remain to be
determined. So far, rHuEPO cannot be recommended to reduce red blood celi
transfusions in anemic critically iII patients.
Introduction
Anemia is a common complication in intensive care patients.18 Many of these
patients receive multiple transfusions, despite the absence of active bleeding.4
In 1990, it was estimated that 85% of patients hospitalized in intensive care for
more than one week received at least one red blood celi unit and that, on
average, patients received two to three units per week.4 More recently, it was
reported that approximately 31% of intensive care patients received
transfusions.9 Transfusion practices in intensive care also vary considerably;
some intensivists use a hemoglobin concentration of 10 g!dL as the transfusion
threshold while others use a much more restrictive approach.1°
Although red blood celI transfusion is a common practice in intensive care,5 the
actual benefits of increasing hemoglobin levels through transfusion have not
been clearly established. Red blood ceN transfusion may increase the delivery of
oxygen to the tissues, but it is not known whether cellular oxygen consumption
actually increases.5’711 Transfused blood is Iow in 2,3-diphosphoglycerate
thereby reducing the ability of the red blood ceils to unload oxygen to the
tissues.12 Moreover, anemia may be a factor interfering with a patient’s ability to
wean from mechanical ventilation.11 Nor is there a consensus on the
advantages of using a high transfusion threshold (Hb 10 g!dL) versus a
restrictive one (Hb 7 gIdL) for accelerating the point at which intubated patients
can be taken off mechanical ventilation.11
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Transfusions also entail the risk of adverse reactions and virus transmission.13
Moreover, patients in intensive care may be more susceptible to the
complications associated with immunosuppression, immunomodulation, and
microthrombosis secondary to red blood ceil transfusion.15’613
Immunomodulation increases the risk of nosocomial infection and potentially a
recurrence of neoplasia.13 Patients receiving blood that had been stoted for
more than 15 days develop evidence of splanchnic ischemia attributable to the
poor deformability of the transfused red blood cells.12 Consequently, there is
growing evidence to suggest that red blood ceil transfusion is flot necessarily
beneficial and, in some cases, may even be harmful.2’4
Given the limitations and risks cf blood transfusion in intensive care patients, a
review cf transfusion practices that takes into account restrictive transfusion
strategy and transfusion alternatives, such as recombinant human erythropoietin
(rHuEPO), is in order. The purpose of this article is to review the literature
concerning the rote of rHuEPO in reducing the need for transfusion in intensive
care patients.
Data Sources
A MEDLINE literature search (1990 to June 2001) was performed to identify ail
controlled, prospective, randomized studies on the use cf rHuEPO in critically iii
adults. The following search terms were used $ erythropoietin, epoetin alfa,
anemia, reticulocytes, hemoglobin, criticai care, intensive care, critical illness
and blood transfusion. The bibliographies of retrieved publications were
reviewed for additional references that may have been missed by computerized
search. Background information concerning anemia cf the critical illness and
blood transfusion was identified through the same MEDLINE search strategy.
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Criteria for red blood ceil transfusion
For many years, a hemogiobin level 0f 10 g/dL45’14 and a hematocrit of 3Q%414
were the transfusion thresholds, particuiarly in the context of surgery.4’14
Howevet, In a muiticenter, randomized, controiled ciinical triai invoiving 838
criticafly iH patients, Hébert et ai recentiy showed that a restrictive transfusion
strategy was just as effective as, and possibiy more effective than, a liberal
strategy.6 The hemoglobin concentrations of patients assigned to the restrictive
strategy of transfusion were maintained in the range of 7 to 9 g/dL, with a
transfusion given when the hemogiobin concentration feu beiow 7 g/dL.6 Among
patient
assigned to the liberai strategy 0f transfusion, the hemogiobin
concentrations were maintained in the range 0f 10 to 12 g/dL, with a threshoid
for transfusion of 10 g/dL.6 The primary outcome was 30-day ail-cause mortaiity.
Secondary outcomes inciuded other mortauity rates and rates of organ faiiure.
Hébert’s study has been a major advance in defining appropriate transfusion
practice in the criticauiy iii popuiation.4 They showed that, overali, there was no
statisticauly significant difference between a restrictive approach to transfusion
and a iiberal one in terms of mortaiity after 30 days.6 Moreover, they found that
among less critically iii patients (APACHE ii score < 20rn), mortauity was
distinctiy iower in the restrictive group (8.7% vs 16.1%; p = 0.03). The same was
true 0f patients under the age of 55 (5.7% vs 13.0%; p = 0.02).6 These findings
suggest that a transfusion threshoid of 7 g!dL and target hemogiobin level of 7
to 9 g!dL are preferabie to a transfusion threshold 0f 10 g/dL and a target
hemogiobin Jevei of 10 to 12 g/dL6 Such an approach is safe for most
hemodynamicaiiy stable coronary patients, with the possibie exception of
patients suffering from acute coronary syndrome.9
Hébert’s study cieariy demonstrates the limitations of red blood ceii transfusion
and the importance of a restrictive approach in intensive care.6 Moreover, any
additionai strategy capable 0f reducing the need for transfusion would be
desirable. One such strategy couid be to optimize endogenous red biood celi
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production by acting on the mechanisms and causes of anemia in patients with
multiple organ dysfunction syndrome (MODS) or sepsis.1
Anemia in Intensive Care
Several factors conttibute to anemia in intensive care patients: numerous blood
draws, occult gastrointestinal bleeding and blood ioss caused by surgical
techniques.1 Deficient erythropoiesis like that seen in chronic inflammatory
disease16 may also explain why patients with sepsis or MODS, in whom
inflammation mediator levels are elevated, develop anemia.13’7’817’18
Erythropoietin, a hormone secreted by the kidneys, triggers the production of
red blood ceils by stimulating the division and differentiation of precursors in the
bone marrow.8’18 Serum erythropoietin levels in normal individuals are in the
range of 5-30 lU/L.9 A decrease in the suppiy of oxygen to the kidneys is the
primary triggering factor responsible for the production of erythropoietin.18 A
sudden drop in hemogiobin usually causes an exponential increase in the
amount of erythropoietin circulating in the bloodstream within minutes or
hours.38’16’18 However, this response is blunted in anemic patients seen in
intensive care and is exacerbated by sepsis.13 Erythropoietin secretion is
blunted when the blood contains high levels of cytokines during inflammatory
diseases or sepsis.’3’16’17 Consequently, endogenous erythropoietin levels in
ambulatory patients with anemia are in the order of 845 + 180 IU/L versus 124 +
13 IU/L for anemic patients with sepsis in intensive care.3 Erythropoiesis
blunting may contribute to the graduai decrease in hemoglobin frequently seen
in this context.3717 Low erythropoietin levels observed in MODS could be a
compensatory mechanism to maintain a good rheology or hemodilution to
overcome the hypercoagulable state frequently seen in that context. In these
patients, optimal delivery of oxygen to the tissues s critical in order to avoid
multiple organ deterioration.17 In addition, anemia can be a major obstacle to
removing the patient from mechanical ventilation. During mechanical
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ventilation, the work done by the respiratory muscles increases the amount of
oxygen consumed by the tissues, increasing the need for oxygen to the heart,
respiratory muscles, and splanchnic circulation.11
rHuEPO use in Intensive Care
rHuEPO stimulates erythropoiesis by binding to the receptors on the surface of
erythrocyte precursor cells in the bone marrow.16 A small number of these
receptors are found on early burst-forming units-erythroid (BFU-E); however,
their numbers increase according to cellular differentiation, reaching their
maximum expression on colony-forming units-erythroid (CFU-E) and
proerythroblasts.16 rHuEPO mainly stimulates the differentiation and proliferation
of CFU-Es. If endogenous erythropoietin concentrations are abnormally low,
rHuEPO administration prevents the destruction of CFU-Es.16 However,
rHuEPO has no impact after red blood cells are released into the bloodstream
because there are almost no receptors on the surface of mature red blood
cells.16 Therapy with rHuEPO was first shown to correct the anemia caused by
chronic renal failure in patients undergoing dialysis.19 lt is also used in clinical
practice for other indications including treatment of anemic chemotherapy
patients with nonmyeloid malignancies, prevention of anemia in surgical patients
and treatment of anemia induced by zidovudine therapy in HIV-infected
patients.19 rHuEPO should routinely be given subcutaneously to maximize its
effects)619 Intravenous administration teads to unphysiologic high peak plasma
erythropoietin concentrations followed by subnormal levels.19 Subcutaneous
administration of rHuEPO induces lower plasma erythropoietin concentrations
but markedly longer elimination half life.16’19 For the treatment of anemia in
patients with chronic renal failure, the usual initial dosage is 80-120 U/kg thrice
weekly. Several larger dosing regimens of rHuEPO have been used in the
surgical setting including 300 U!kg daily for 14 days or 600 U/kg weekly for 4
weeks.2°
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Given the precarious condition cf patients in intensive care, there would have to
be a rapid, significant response to rHuEPO administration for their transfusion
needs to change. In 1990, it was estimated that approximately 40% of
transfused intensive care patients only received transfusions during their first
week of hospitalization.4 However, those hospitalized for more than a week
were transfused consistently every week.4 Recent studies have shown that rapid
stimulation of erythropoiesis is possible in intensive care patients with high
doses of rHuEPO (Table j)271721
In .a prospective, randomized, pIacebo-controlled study, Gabriel et al studied
rHuEPO response in 19 patients admitted to intensive care with MODS following
major abdominal surgery or major trauma.17 Erythropoietin levels, cytokines
levels and reticulocyte counts were the major outcomes. The patients were
tandomized to receive either 600 U/kg rHuEPO or a placebo intravenously three
times a week for three weeks. Ail patients also received intravenous iron, folic
acid, and vitamin B12 supplements. Patients in both groups were transfused to
maintain a hematocrit > 30%. Nine patients received rHuEPO and 10 patients
received a placebo. Two patients in the rHuEPO group required massive
transfusions following episodes of major bleeding. In terms of the severity of
their disease (APACHE Il score15) and the Iength of stay in intensive care, the
groups were comparable. Gabriel’s study showed that high doses of rHuEPO
stimulated erythropoiesis in patients with MODS, despite elevated cytokine
Ievels.17 At the end of the thitd week of treatment, a statistically significant
increase in erythrocytes was observed in the patients who had received
rHuEPO compared with those who had received the placebo (4.0 % + 0.9 vs 1 .9
% + 0.5 respectively; p < 0.05). A statistically significant difference was
observed between the placebo group and the rHuEPO group in terms of serum
erythropoietin at the first week of treatment (30.4 ± 7.7 U!L vs 150.2 ± 27.6 U/L
respectively; p<0.05) showing a biunted erythropoietin response in MODS. In
the absence of major bleeding (<6 units of packed red blood cells per week), 2
of 7 rHuEPO patients required red ceIl transfusions during the third week of
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treatment compared with 6 0f 10 control patients (p 0.335). However, this
study was flot designed to assess the impact of rHuEPO on the need for
transfusion.
In an open, randomized study, van Iperen et al evaluated rHuEPO response in
36 intensive care patients with a hemoglobin count of < 11.2 g/dL (or a
hemoglobin 0f < 12.1 g/dL in coronary patients).2 The patients were divided into
three groups of 12 each and received either 1 mg folic acid daily for 14 days
(control group), 1 mg folic acid daily + 20 mg iron iv daily for 14 days (iron
group) or 1 mg folic acid daily + 20 mg iron iv daily for 14 days + 300 U/kg
rHuEPO subcutaneously every two days for five doses (rHuEPO group). The
major outcomes were serum erythropoietin levels and increase in the
reticulocyte counts compared with baseline values and compared with the two
other groups. The groups were comparable in every regard except length of
stay in intensive care, which was longer for the patients in the control group than
for the patients in either the iron group or the rHuEPO group (58 ± 31 days vs
29 ± 18 days and 37 ± 20 days respectively; p < 0.05). Patients in each of the
groups were transfused on the same transfusion threshold : a hemoglobin count
of 8.9 g/dL or 9.7 g/dL for coronary patients. The resuits of this study showed
that when rHuEPO was administered, erythropoiesis was rapidly stimulated in
intensive care patients. A statistically significant increase in the number of
circulating red blood ceils was observed after 6 days in the patients who
received rHuEPO compared with baseline values and after 8 days compared
with the two other groups.2 Reticulocyte counts increased in the rHuEPO group
from 56 ± 33 x 1091L to a maximum 0f 189 ± 97 x 109/L on day 13. However, it
would have been helpful if the results had been presented in terms of hematocrit
instead of reticulocyte count. A statistically significant difference was observed
between the placebo group or the iron group in terms 0f serum erythropoietin
atter 10 days of treatment compared to the rHuEPO group (19 ± 8 U1L vs 16 ± 5
U/L vs 166 ± 98 U/L respectively; p<0.05) showing a blunted response in that
mixed population of anemic critically iII patients. However, no differences
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between the groups were observed in terms of hemogiobin concentrations
during the entire study. On average, 12 ± 14 red blood ceil units per patient
were transfused over a three-week period in the control group versus 5 ± f and
f ± 7 units for those in the iron group and rHuEPO group, respectively.
However, this open study did not measure the impact of rHuEPO administration
on the need for transfusion, nor was it designed to.2
Corwin et ai proposed the use of rHuEPO to reduce the need for transfusion
and conducted a prospective, muiticenter, doubie-blind, placebo-controiled,
randomized study to measure the impact of rHuEPO administration on the need
for transfusion in intensive care.7 To our knowiedge, this is the oniy study to do
0 so in muitidiscipiina intensive care. b quaiify for the study, patients had to be
over the age of 18 years and have a hematocrit of < 38%. They could not have
an iron, vitamin B12 or folate deficiency. The many exclusion criteria inciuded
patients with active bieeding, neutropenia or thrombocytopenia; patients
requiring vasopressive amines other than dopamine administered at a renal
dose; patients with unmanaged hypertension, chronicaiiy dialyzed patients; and
patients with a history of liver failure, cirrhosis, hepatic encephalopathy, seizures
during the previous 6 months, recent cerebrovascuiar accident and recent
thromboemboiic disease. During their stay in intensive care, patients received
either 300 U/kg of rHuEPO or a placebo subcutaneousiy once a day for five
days, foilowed by a dosing schedule of every two days for a minimum of two
weeks, and for a maximum of six weeks. The primary end points was to
measure the total number of transfusions per group and the percentage of
patients in each group who either received at Ieast one unit of red blood ceNs or
died from day 8 to day 42 of the study. Administration of the medication was
discontinued temporariiy if the hematocrit exceeded 38%. Ail patients aiso
received either an oral or a patenterai iron suppiement. Whether oral vs
patenterai ton use was simiiar between groups was not mentionned. In ail, 160
patients took part in the study: 80 in the rHuEPO group and 80 in the controi
group. At randomization, the two groups were comparable in terms of age,
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hematocrit, erythrocyte count and severity of disease (APACHE li score15).
There was a clinically and statistically significant decrease in the total number of
transfused red blood celi units in the group receiving rHuEPO, compared with
the placebo group (166 vs 305 respectively; p < 0.002). Forty-five percent of
patients in the rHuEPO group either received at least one red blood cell unit or
dieU between day 8 and day 42 of the study compared to 55% for the placebo
group (relative risk 0.8; confidence interval 95% from 0.6 to 1.1). No statistically
significant difference was observed between the groups in terms of mortality or
incidence of side effects attributable ta rHuEPO (deep vein thrombosis 4 vs 4,
thrombocytopenia 9 vs 3 or thrombocytosis 6 vs 2; rHuEPO vs placebo,
res pectively).
The results of this study are encouraging; this suggests that rHuEPO is a
potential alternative to allogenic blood products in intensive care. We should
point out, however, that this study did not use any transfusion criteria; the
decision ta transfuse was left to the doctor’s discretion. The study did not
document the hemoglobin value or other criterion for transfusing patients. It
would therefore be difficuit and premature ta conclude that rHuEPO
administration in intensive care can reduce the number of transfusions. Nor did
the authors indicate the length of stay in intensive care, making it difficuit to
interpret their resuits given that transfusion rates vary according to length of stay
in intensive care4.
Moreover, because this study used many exclusion criteria, it cannot easily be
generalized or applied to a mixed population of critically III patients. Many of
these exclusion criteria are typical of patients hospitalized in intensive care.
Finally, it would have been helpful if the results had been analyzed based on a
disease severity score ta target patients most likely ta benefit from this
a p proach.
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Lastly, in a double-blind, multicenter, prospective trial, Stiil et al studied rHuEPO
response in a special population of 40 acutely burned patients21. Patients with
burns from 25% to 65% total body surface were randomized to receive either
300 U/kg rHuEPO intravenously or a placebo daily for 7 days. The dose was
then decreased to 150 U/kg rHuEPO every other day for 23 days. Patients in
both groups were transfused to maintain a hemoglobin of 10 g/dL or 8 g/dL after
major surgeries. There were no significant differences between groups at
enroilment in patient characteristics. After 30 days, there was no statistically
significant difference in hemoglobin, hematocrit, blood loss and transfusion
requirements.
Validity of trials and analysis
A critical appraisal of randomized controlled trials is summarized in table
22717,2123 The method of randomization is not described in three studies.2’17’21
The timing of randomization and concealment of allocation is indicated in table
2. Baseline balance was obtained in three of these trials.7’17’21
Only two studies7’21 presented an intention-to-treat analysis. AIl patients who
were entered into the trial of Corwin et al7 were accounted for at its conclusion
and were followed for a total of 42 days after randomization. In the study of
Gabriel et al’7 patients who entered the study but who were treated for less than
3 weeks because of discharge from the intensive care unit or death, were
excluded from data analysis. One patient was withdrawn from the study of van
Iperen et al2 because of fulminant bleeding and 15 patients were excluded from
data analysis. The reporting of losses is indicated in table 2. Two studies looked
at the impact of rHuEPO administration on the need for transfusion7’2 but only
one clearly mentioned that a power analysis was performed before random
allocation.7 The statistical analysis was valid in ail trials.
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One study was an open trial2, it is unknown whether the groups were treated
equaliy spart from the experimentai therapy. Oniy twa studies were double
blinded721 whereas the biinding was not mentioned in the study of Gabriel et
al.17
The outcome was considered clinically important only in the study of Corwin et
al7 and in the study of Stiil et ai.21 The other triais2’17 reported oniy end points on
laboratory measurements whereas a positive ciinicai impact on the total number
of red biood celi units transfused was demonstrated in Corwin’s study7.
Future Studies
in recent years, there has been increasing interest in restricting red blood celi
transfusion. Hébert et al recentiy proposed a restrictive strategy to transfusion
that significantly reduces transfusion in intensive care without affecting
mortality.6These recent data should be taken into account in any assessment 0f
the impact of rHuEPO administration on the need for transfusion in intensive
care. The Hébert study showed that with a restrictive approach to transfusion it
is possible to achieve a statisticaiiy significant reduction in the mean number cf
transfused units per patient when compared with a liberai approach (2.6 ± 4.1 vs
Ø 5.6 ± 5.3 respectiveiy; p < O.O1).6 in addition, the restrictive approach made it
possible ta compieteiy avoid transfusion in 33% of patients, whereas ail of the
patients treated with a liberal approach received at ieast one transfusion.6 In
future studies on rHuEPO administration in intensive care, a transfusion
threshold 0f 7 g/dL should be used for most critically iii patients. Such studies
wouid have ta show that rHuEPO administration combined with a restrictive
approach advocated by Hébert resuits in an additionai significant decrease in
the need for transfusion, compared with use of the restrictive strategy alone.
Other potential benefit to the anemic criticaiiy iii patient resuiting from rHuEPO
can be the possibiiity to increase oxygen deiivery without exposure to the
negative effects oftransfused blood.24
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Although there have been no studies on the safety cf administering high doses
of rHuEPO in intensive care, the incidence of adverse effects does not appear
ta be higher compared to placebo.2’7 Corwin et al did not report any statistically
significant difference between rHuEPO and placebo in terms of mortality, deep
vein thrombosis or thrombocytopenia.7 No statistically significant differences in
the frequency of thrombocytosis have been reported.2’7 However, an increase in
blood pressure is generally observed in patients with renal disease who take
rHuEPO chronically,16 and this increase in blood pressure could also be found in
intensive care patients. The level of care provided in an intensive care setting
allays these concerns; however, further studies wiIl be necessary ta determine
the
safety cf administering high doses of rHuEPO in this context. Moreover,
some authors report that elevated endogenous erythropoietin levels,
independent cf hemoglobin concentrations, are indicative of a poor prognosis in
patients in septic shock.25 Future studies wilI need to be performed ta determine
if elevated erythropoietin levels may be harmful to the patient.
The amplification of erythropoiesis that resuits from the administration of
rHuEPO increases the need for Iran.16’19 Consequently, these patients must
receive an iron supplement to optimize their response and prevent functional
iran deficiency.16’9 The studies cited in this article describe variaus types of Iran
supplementation.2’7’17’2’ In Gabriel’s study,17 patients received 13.5 mg iran
intravenously as weIl as a source cf oral Iran in their feedings. In van Iperen’s
study,2 patients received 20 mg Iran iv daily. In Corwin’s study,7 patients
received 150 mg of elemental iran orally each day. PatenteraI iron was given ta
patients who were unable ta take oral iran (dose flot described).7 In StiII’s study,
oral iran was given at the discretion cf the clinician.21 A patients need for iran
subsequent ta rHuEPO administration may exceed the amount that can be
provided by oral supplementation, a factor that limits its usefulness.16 The
intramuscular route of administration is often erratic and should be used with
precautian in patients on anticoagulation therapy. Consequently, the
intravenous route appears to be the route of choice for most critically il! patients.
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However, only iow doses of intravenous iron are probably appropriate in
intensive care because iron can promote the growth of bacteria.26 Iron
suppiementation should be administered to ail patients except those with
increased serum iron and transferrin saturation.16 The use of serum ferritin as a
marker for iron deficiency is iimited in MODS since inflammation can resuit in a
false elevation 0f the ferritin values.27 Care should be taken in future studies to
optimize iron supplementation and evaluate folates and vitamin B12 deficiency
so that the real efficacy of rHuEPO in intensive care is not underestimated.
Moreover, rHuEPO was administered ïntravenously in two studies7’21 but
should be administered subcutaneously to maximize its effects.1619
Finaily, rHuEPO is a very expensive medication and pharmacoeconomic
analysis shouid be performed in future studies. The cost of rHuEPO as used in
Corwin’s study was on average $ 1,890 per patient.7 Future economic anaysis
should take into account the cost of rHuEPO, iron supplement, blood transfusion
) and the potential savings resulting from the avoidance of adverse reactions
related to blood transfusion.
Summ a ry
In summary, few randomized controlled triais explore the raie of rHuEPO in the
intensive care. Only one was a large randomized clinical triai but presents many
limitations. Future outcome and safety studies comparing rHuEPO vs placebo
wilI need to be performed with c)inicai end points such as end organ morbidity,
mortality, transfusion requirements and pharmacoeconomic analysis. rHuEPO
appears to improve the erythropoietic response but optimal rHuEPO dosage
and the real impact of rHuEPO on the need for transfusion in intensive care
remain to be determined. So far, rHuEPO cannot be recommended ta reduce
red biood celi transfusions in anemic criticaliy iIi patients.
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ARTICLE Il (Table 1): Randomized studies on the use of rHuEPO with aduit
patients in intensive care
Gabriel et al
(1998)17
Randomized,
prospective,
multicenter,
double
blinded
placebo
controlled
rHuEPO 300 U/kg iv daily for 7
days, then 150 U/kg every 2
days for 23 days
t oral ferrous sulfate
placebo
± oral ferrous sulfate
or
placebo
+ iran 13.5 mg iv + folic acid 0.4
mg iv + vitamin B12 5 mg iv daily
rHuEPO 300 U/kg sc
daily for 5 days, then every 2
days for a maximum of 6 weeks
+ 150 mg of elemental iron orally
or
placebo
÷ 150 mg cf elemental iron orally
No significant
differences in
hemoglobin, hematocrit,
blood loss and
transfusion requirements
• No significant
differences in the need
for transfusion
• rHuEPO significantly
reduced transfusions
requirements vs placebo
(166 vs 305; p<0.002).
• 45% patients either
transfused at teast once
or died with rHuEPO vs
55% with placebo (NS)
No significant
differences in mortality
or incidence cf side
effects
Stili et al
(1995)21
References Design Patients Medications Outcomes
IRandomized,
prospective,
multicenter,
double
blinded,
placebo
controlled
Randomized,
prospective,
placebo-
contra I leU
or
40 acutely
burned
patients
19 patients
in intensive
care with
MODS
160 patients
in medical
and surgical
intensive
care
rHuEPO 600 U/kg iv 3 times a
week for three weeks
+ iron 13.5 mg iv + folic acid 0.4
mg iv + vitamin B12 5 mg iv daily
• Significant increase in
erythrocyte count with
rHuEPO vs placebo (4%
± 0.9 vs 1.9% ± 0.5;
p<O.O5)
Corwin et al
(1999)
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van Iperen et al
(2000)2
36 patients
in medical,
surgical,
trauma and
ne u rolog cal
intensive
care
Folic acid 1 mg iv daily for 14
days
or
folic acid 1 mg iv daily + iron 20
mg iv daily for 14 days
or
folic acid 1 mg iv daily + iron 20
mg iv daily for 14 days +
rHuEPO 300 U/kg sc every 2
days X 5 doses
Reticulocyte count
increase with rHuEPO
vs baseline values ffrom
56±33x109/Ltoa
maximum of 189 ± 97 x
109/L on day 13; p<0.05)
• Significant increase in
the number of red blood
ceil with rHuEPO vs
placebo or iron
Randomized,
open trial
• No significant
differences in
hemoglobin
concentration
rHuEPO: recombinant human erythropoietin ; iv: intravenously; MODS: multiple organ dystunction
syndrome; sc : subcutaneously ; NS : not statistically significant
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ARTICLE II (Table 2): Randomized controlled trials with rHuEPO in the
intensive care unit: crïtical appraisal
(adapted from Doig GS22)
Study StiiV’ Gabriei Corwin’ van Iperen
Randomization technique
Method described N N Y N
Conceaied Y N/R Y N
Timing ICU day 3 ICU day 1 1CU day 3 ICU day 1 to
discharge
Baseline balance Y Y Y N
Ail patients accounted
Foiiow-up Upto3Od Upto2l U Upto42d Upto2l d
Reporting of iosses N Y Y Y
Ail patients anaiyzed Y N Y N
Blinding Y N/R Y N
Equally treated Y No clear Y No clear
evidence evidence
Study outcome
Chnicaity important Y N Y N
Analysis of resuits
Vaiid Y Y Y Y
Power anaiysis N/R N/R Y N/R
Helpful to patients
Benefit of intervention on outcome No benefit No benefit Y No benefit
Study level 11t lb
N :no ; Y:yes;N/R $ not reported; ICU : intensive care unit; U :days ;
* Sackett’s criteria for the
clin cal appraisai of evidence23 smali randomized trials with uncertain resuits; Large
‘4
I
randomized triais
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ARTICLE III : Iron metabolism in critically iII patients. Crit Care 2004;8:356-
*
62.
Martin Darveau, André Y. Denauit, Normand Biais, Éric Notebaert
*
Cet article a été commenté par l’éditeur du Critical Care : Piagnerelli M, Vincent JL. Role ofiron
in anaemic critically III patients : its time to investigate ! Crit Care 2004,8:306-307.
ABSTRACT
Critically iII patients frequentiy develop anemia due to severai factors. iron
withholding mechanisms caused by inflammation contribute to this anemia. The
iron metabolism imbalances described or reported in ail intensive care studies
are similar to the values observed in anemia of inflammation. The administration
of iron could be useful in the optimization of recombinant human erythropoietin
activity however this couid be at the expense of bacterial proliferation. Since
there is a lack of evidence to support either oral or intravenous iran
administration in intensive care patients, further studies are necessary to
determine the efficacy and safety of iron supplementation in conjunction with
recombinant human erythropoietin in critically III patients. We review the
mechanisms leading to iron sequestration in the presence 0f inflammation. This
article also reviews the literature describing the iron status in critically iii patients
and explores the role of iton supplementation in this setting.
)
Keywords : iron metabolism, critical illness, erythropoiesis
FID = functional iron deficiency; ICU = intensive care unit; IL-1 = interleukin-1;
IL-6 = interleukin-6; IV = intravenous; MODS = multiple organ dysfunction
syndrome; rHuEPO recombinant human erythropoietin; TNF = tumor necrosis
factor
INTRODUCTION
Recent observational studies have shown that most patients in the intensive
care unit (ICU) become anemic within a few days [1-3]. In Europe,
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N approximately 37% of patients receive transfusions and close to 70% cf those
remaining in the ICU for more than seven days are transfused [1]. The CRIT
STUDY showed similar resuits in the United States [2]. A number of factors
contribute to this anemia, including the acute inflammatory reaction typical of
these patients [5]. Anemia of inflammation has been clearly described in
patients with cancer, chronic inflammatory disease and chronic infection [5-1 0].
This type of anemia is related to the release cf mediators that cause a blunted
erythropoietic response and activation cf red blood ceil catabolism by
macrophages. The inflammatory state also resuits in decreased mobilization of
iron stores from the reticuloendothelial system, leading te the development and
persistence of anemia [5-10].
In recent years, special attention has been paid te Iimiting the number of
transfusions received by ICU patients. Limiting blood collection [1] and restrictive
transfusion thresholds [11] are among the strategies that have been adopted for
) blood conservation. Although the optimal dose of recombinant human
erythropoietin (rHuEPO) in the intensive care setting has yet to be determined,
its use constitutes another blood conservation strategy [12,13]. Erythropoietin’s
ability to stimulate erythrocyte production is highly dependent on the availability
cf iron. Understanding iron metabolism in this patient population is important in
) order to act on the mechanisms and causes of anemia in critically iii patients.
The decrease in iron availability seen in inflammatory diseases may contribute
to inadequate erythropoiesis in ICU patients. Is the iron metabolism imbalance
seen in chronic inflammatory states similar to that found in ICU patients? Te
what extent do these disturbances affect erythropoiesis and the patient’s
response to exogenous erythropoietin? Should iron supplements be
administeced? The purpose cf this article is to review the impact of inflammation
on iron status and to review the studies that describe iron metabolism in ICU
patients. We also explore the role of iron supplementation in this setting.
)
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IRON WITHHOLDING MECHANISMS IN THE PRESENCE 0F
INFLAMMATION
Most of the iron avallable for erythropoiesis cornes from the catabolisrn of
senescent red blood celis by the macrophages in the reticuloendothelial system
[6-10]. The iron, transported by transferrin, binds to receptors on the surface of
the erythroblasts and is used in hemoglobin synthesis [6-10]. The iron also
binds to apoferritin to create iron stored in the form 0f ferritin. Under normal
conditions, there is a balance between the iron transport paths and the iron
stores [6-10].
Ferritin is an infiarnmatory protein (acute-phase reactant). The synthesis of
ferritin is increased by circulating cytokines such as interleukin-1 (IL-1) and
turnour necrosis factor (TNF). When these inflammation mediators are present,
iron stored in the forrn of ferritin tends to increase and the mobilization of iron
stored from the reticuloendothelial system tends to decrease. The balance
between the arnount of iron available for erythropoiesis and the stored iron is
disturbed (Figure 1) [6-10]. Hypoferrernia rapidly sets in due to an increase in
the iron-binding capacity of ferritin to the detriment of transferrin. The severity of
the hypoferremia depends on the severity of the underlying inflammatory
disease [6].
IL-l also stimulates lactoferrin synthesis. Lactoferrin is a circulating protein that
binds iron with greater afflnity than transferrin [6,7,9]. In the presence of
inflammation, iran bound to lactoferrin is captured by the macrophages, then
stored in the form 0f ferritin, thereby withholding iron from the erythroid
precursors (Figure 1) [6,7,9]. The recent dernonstration that a novel protein,
hepcidin, is greatly upregulated in response ta inflammation via interleukin-6 (IL
6) is yet another potential mechanism of iron sequestration [14]. Hepcidin could
be a central mediator of decreased iron absorption through the gut,
sequestration of iron in macrophages and has shown homology ta naturally
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occurring antimicrobial proteins [14]. Changes related to inflammation therefore
lead to less iron bound to transferrin and less iron available for erythropoiesis [6-
10]. This process has been hypothesized to have evoived as a “tug-of-war”
phenomenon resuiting in an iran deficient milieu which would eaU to
compromised microorganism proliferation (Figure 1) [7,9].
Overaii, these mechanisms resuit in a decrease in serum iron < 9pmolIL, a
decrease in transferrin levels < 3 g!L and a decrease in the transferrin saturation
percentage between 10% and 20%, with normal or eievated ferritin leveis> 300
pg/L [8,10]. Elevated ferritin levels in infiammatary states make It difficuit to
evaluate Iran stores. However, a patient presenting with a ferritin concentration
> 200 ugIL probably does not have an Iran deficiency whereas a value of < 30
pg/L does indicate iran deficiency (ferritin levels between 30 ta 200 ug/L in
inflammatory conditions) [6,10].
p)
In contrast with these Iran deprivation mechanisms, it seems that iran deficiency
cauld impair immune defense. Little evidence is available on Iran and its effects
on direct immunity. However, in vitro studies suggested that Iran deficiency
depresses some aspects of cell-mediated immunity [15]. In a review of the
literature, Oppenheimer reported deleterious effects of Iran deficiency an
lymphocyte, neutrophil and macrophage function [1 5]. Whether these effects
depend on the severity of Iran deficiency 15 nat knawn. Nat anly Iran deficiency
but Iran overload also seems ta impair polymarphanuclear leucocyte function,
reducing phagacytic functian and bacterial killing [16]. Data regarding Iran and
its effect on immune system are canflicting. More studies are needed ta clearly
elucidate the raie of Iran on immunity.
IRON METABOLISM IN ICU PATIENTS
inflammation is implicated in many criticaily iii disorders. indeed, ciinical
evidence of systemic inflammation is present in almost alt patients deveiaping
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) multiple organ dysfunction syndrome (MODS), a common complication
observed in critically iII patients [16]. The severity of the host inflammatory
response is highly related to the development of MODS and is frequently seen
in patients with sepsis. The anemia 0f inflammation is a hypoproliferative
anemia defined by a low serum or plasma iron concentration in the presence 0f
adequate reticuloendothelial iron stores [5]. It is possible that iron metabolism
involved in the anemia of chronic disease is similar to the anemia seen in
critically Il patients because of the presence 0f inflammatory mediators in both
conditions. To describe iron metabolism in critically iII patients, a search was
pertormed on MEDLINE database from 1966 to December 2004 for articles
describing iron metabolism in adult critically iII patients. The term “critical illness”
was combined with the terms “iron”, “erythropoiesis” and “anemia”. AIl English
language articles describing iron metabolism in the ICU setting were retained.
The bibliographies 0f these articles were reviewed for additional references.
Five observational studies described iron metabolism in ICU patients [3,18-211.
One study provided indicators 0f iron status [22]. AIl studies described iron
metabolism in a population of nonbleeding, acutely iII patients. Studies on iron
metabolism mediators are summarized in Table 1.
Two studies described iron metabolism throughout the ICU stay [3,18]. The first
) study described iron status in critically iII surgical patients. In 1989, in a study
involving 51 patients, Bobbio-Pallavicini et al. observed a decrease in serum
iron and elevated ferritin levels in over 75% of patients on their third day of
hospitalization in the surgical intensive care unit [18]. Table 1 shows the
variations in iron metabolism indicators during intensive care for aIl patients.
Ferritin values remained abnormally elevated among aIl patients during their
stay in ICU. Patients with sepsis leading to MODS had the highest ferritin
values. lndeed, among patients who developed post-operative sepsis, there was
a significant drop in hemoglobin (107.3 gIL vs 125.7 g/L; p < 0.001), a
significant increase in ferritin levels (1585 pgIL vs 641 pg/L; p< 0.001) and a
significant dectease in transferrin (1 .44 gIL vs 1 .95 gIL, p < 0.001) compared to
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their pre-sepsis state. However, sepsis did not significantly affect serum iron
levels. When sepsis resolved, the transferrin and hemoglobin values increased.
Ferritin decreased dramatically with sepsis resolution (1585 pg!L vs 472 pgIL; p
<0.001).
The incidence, severity, characteristics and causes of anemia in 96 patients
who had been in a medical ICU for more than three days were assessed in the
second study [3J. Fifteen per cent cf the patients experienced acute bleeding;
39% of the patients were transfused during their stay in the ICU. While in the
ICU, 71 patients (74%) developed anemia (Hb < 110 gIL) which could not be
explained by blood loss alone. Elevated ferritin values and decreased transferrin
saturation values were observed in these patients (Table 1). During the first 2
weeks of the ICU stay, more than 50% of patients had abnormal serum iron
concentrations. These values continued to be observed for over four weeks, as
reported in the study performed by Bobbio-Pallavicini et al. [18]. lncreased iron
) sequestration secondary to inflammation could explain the increased ferritin
levels and the reduced serum iron concentration and transferrin saturation
observed in these studies.
Two other studies in critically iII patients reported their observations on iron
metabolism on the first few days of admission [19,22]. In the fisrt study,
Rodriguez et al. present iron metabolism values for patients with hematocrit <
38% on the second or third day in the ICU [19]. These values corne from
screening data for a study comparing rHuEPO administration to placebo in
surgical and rnedical ICU patients [23]. 0f the 184 patients screened for this
study, 16 had transferrin saturation < 15% or ferritin <50 pg/L and were not
included. Eight patients had a vitarnin B12 deficit or a folate deficit and were also
excluded. The remaining 160 patients were included. The admitting diagnoses
were pneumonia (24%), respiratory diseases (21%) and trauma (15%). The
values for serurn iron, ferritin and transferrin saturation for the 160 patients are
) comparable to values seen in anemia cf inflammation and are presented in
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) Table 1. The mean hemoglobin at the beginning of the study was 103 ± 12 gIL.Although these values were measured at baseline, prior to the administration of
the first dose of study medication, this study was flot designed to study iron
metabolism in consecutive patients.
The second study, conducted by Elliot et al., reported iron metabolism
abnormalities in 25 ICU patients with acute failure of at least one organ [221.
Patients with chronic renal failure, coagulopathy or active bleeding were
excluded. In the majority of patients in the ICU for more than 12 hours, they
found decreased mean serum iron levels (1.0-12.6 pmol/L), increased mean
ferritin Ievels (37-2376 pg/L) and decreased mean transferrin levels (0.57-2.46
gIL). Ferritin values were abnormally elevated (>300 pgIL) in 16 patients and
greater than 1000 pgIL in three patients. Iron metabolism imbalances set in
fairly quickly after ICU admission, along with the inflammatory process reflected
by the raised concentrations of IL-6 and C-reactive protein. The mean
) hemoglobin at admission was between 80 et 110 g!L. The anemia observed in
the Rodriguez and Elliot studies was flot secondary to active bleeding or
coagulopathy because these etiologies were exclusion criteria [19,22). However
abnormal iron metabolism could have contribute to this disorder. Mean values
are not reported in this study and therefore are flot presented in Table 1. It
should be noted that the patients in this observational study received a daily 200
mg supplement of oral ferrous sulfate (or equivalent) that may have affected the
results.
Finally, patients admitted to the ICU for multiple trauma also seem to quickly
develop hypoferremia secondary to inflammation. Iron metabolism in 23
severely traumatized patients was evaluated by Hobisch-Hagen et al. [20]. On
admission to the ICU, they presented with an average hemoglobin level of 100
g/L (68-129 g/L). Twelve hours after admission to the ICU, ferritin levels were
markedly elevated f> 300 pg/L). The elevated levels persisted beyond one
) week. Reduced serum iron concentrations on the second day of hospitalization
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were statistically significant, compared to admission, and remained lower for
more than a week. Serum transferrin was low and did flot change during the
ICU stay. Indicators of iran status for this study are presented in Table 1 and
compatible with iron parameters usually seen in the presence 0f inflammation.
In summary, these observational studies ail demonstrate that critically III patients
present a decrease in availability of Iran along with an elevated ferritin levels. In
light of the data presented, iron metabolism in ICU patients seems ta behave in
the same way as in chronic inflammatory disease. The iran metabolism
imbalances described or reported in ail of the studies are similar ta the values
abserved in anemia of inflammation. lndeed, elevated ferritin > 300 pgIL, serum
iran < 9pmal/L, transferrin saturation between 10% and 20%, and transferrin
levels < 3 gIL are generally abserved in critically iii patients (Table 1). Iron
metabolism disorders set in within the first few days. Ferritin remained at
particularly elevated levels throughout their ICU stay, reflecting the inflammatory
) condition of these patients. Therefare, iran metabolism disorders probably
cantribute ta the anemia abserved in ICU patients.
Functional iron deficiency (FID)
Unlike iron deficiency anemia, patients with inflammation may have normal iran
stores but might present a FID. FID refers ta the inability ta use iran efflciently
far erythropaiesis, in spite of adequate iran stores. FID may develop with
rHuEPO therapy and might be a cause 0f poor respanse. FID is abserved in
chronic dialysis patients receiving rHuEPO. The increased erythropoiesis
activity induced by rHuEPO exceeds the amount of functionally available Iran.
FID may aiso accu r in inflammatory conditions when the iran is lacked away and
stored by the reticuloendothelial system, preventing the release of the iran
required for erythropaiesis. A decrease in transferrin saturation will accur in
spite of normai or elevated ferritin. FID has been defined by the presence of
) mate than 10% of hypochromic red blood ceils. An observational study on the
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prevalence of FID on admission to the ICU was conducted by Pafferil et al. on
51 patients [21]. In this study, a patient was ccnsidered to have a FID if more
than 10% cf the red blood celis were hypochromic. Upon admission to the ICU,
35% cf patients (95% Cl 22-48%) presented FID. The mean APACHE II scores
of patients with and without FID were comparable. Anemia was no more severe
among patients with FID than in those without FID (average hemoglobin
concentration cf 107 gIL vs 108 g!L respectively). The mean length of stay in the
ICU was statistically increased among patients with FID (7.6 days vs 3.3 days; p
< 0.0007). The severity of FID aIse correlated with the duration of ICU stay.
Thus, FID could reflect the severity of the critical illness. However, FID was not
) associated with APACHE II scores and no difference in the mortality was
observed between the two groups. 0f course, this could be due to a Iack of
power and further studies are needed to determine whether FID in critically iII
patients is simply a marker cf nutritional status or a predictor for outcome. Iron
stores are difficuit to evaluate in the presence cf inflammation because ferritin is
frequently increased. The ferritin values of both groups of patients are presented
in Table 1.
SHOULD WE SUPPLEMENT CRITICALLY ILL ANEMIC PATIENTS WITH
IRON?
)
Considering the physiopathclogy cf the anemia cf inflammation, it s unhikely that
ton supplementation would further stimulate erythrcpciesis unless iron
deficiency is masked by elevated ferritin levels [6,7]. Only one randcmized
open-label prospective study evaluated erythropoietic respcnse to the
administration of iron supplementation in anemic critically iII patients [24]. In this
study, aIl patients (36 patients) received 1 mg fclic acid daily. One-third cf the
patients received no additicnal therapy. The iron group (12 patients) received 20
mg intravenous (IV) ircn supplementation daily for 14 days. The rHuEPO group
(12 patients) received IV ircn with 300 U/kg cf rHuEPO every two days for 14
days. Compared te the levels in the other two groups, the elevation in
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) reticulocyte counts was statistically significant only in the rHuEPO group.Reticulocyte counts increased in the rHuEPO group from 56 ± 33 x 1091L to a
maximum of 189 ± 97 x 109/L on day 13. No such increase was seen in the iron
group. No significant difference was observed between the three groups in
terms of hemoglobin concentration.
Iron supplementation with rHuEPO
Administration of rHuEPO generally makes it possible to alleviate anemia
secondary to chronic inflammatory disease. A few studies bave shown that
rHuEPO administration also stimulates erythropoiesis in ICU patients with acute
inflammatory states [12,13]. Recently, a large-scale study demonstrated that
rHuEPO together with oral iron suppiementation reduced the need for biood
transfusions in ICU patients [13]. The amplification of erythropoiesis that resuits
from the administration of rHuEPO increases the need for iron. Consequently,
) rHuEPO must be used in conjunction with an iron supplement to optimize the
eryhropoietic response and prevent FID. Given the high prevalence of FID in
ICU patients [21], it would appear essential to provide iron supplementation for
critically iii patients receiving rHuEPO.
Oral suppiementation such as that used recently in the study by Corwin et al.
[13] may not be optimal for aIl ICU patients because the gastrointestinal tract is
not aiways functional and iron absorption is poor and erratic. Moreover,
decreased iron gut absorption by increased hepcidin production and other
mechanisms (particuiarly reiated to the underlying condition of the patient) may
predispose to inadequacy of oral iron therapy. Nevertheless, a significant
reduction in transfusion needs was shown in this study [13].
Whether iron supplementation is necessary in these patients or whether the
response might have been improved with IV iron remain to be determined. ton) supplementation clearly improves the response to rHuEPO. t has been
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that IV iron administration with rHuEPO is beneficial for many dialysis patients
and has become standard therapy for several patients [25]. Furthermore,
administering an IV iron supplement with rHuEPO could make it possible to
optimize erythropoietic response in inflammatory states, as demonstrated in
patients with rheumatoid arthritis [26] and Crohn disease [27]. However, IV iron
supplementation in the ICU seffing may prove hazardous, given the
hemodynamic adverse effects that are possible with certain formulations of
parenteral iron and the risk to promote the growth of bacteria.
Iron supplementation and risk of infection
Iron is an essential component of bacterial growth [9,28]. Iron sequestration
du ring inflammation could represent a defense mechanism [9,28]. However, iron
chelation with siderophores allows bacterial proliferation in a reduced-iron
environment [9,28]. Therefore iron administration could in theory increase the
) host susceptibility for bacterial infections.
No data on critically iII patients are available to support such a hypothesis. The
EPIBACDIAL study performed in 988 patients with chronic renal failure requiring
hemodialysis did not observe a relationship between iron administration and
bacteremia (54.0% in those supplemented with iron vs 52.9% in those without;
p=0.88) [29]. The data from the EPIBACDIAL trial were revised by Hoen et al. to
evaluate the potential role of IV iron administration on the risk of bacteremia
[30]. High-frequency and high-dose IV iron administration were associated with
an increased incidence of bacteremia . The incidence also increased if rHuEPO
was given (RR 5.5; 95% CI 1.29 to 23.5). These data from chronic renal failure
patients could suggest a link between IV iron administration and infection.
Therefore, IV iron administration to ICU patients who are already infected could
be risky.
b
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In the Corwin et al. study, oral iron supplementation was given with rHuEPO to
aIl patients[13] . If oral iron was flot tolerated, patients received IV iran
supplementation. Despite the fact that oral iron administration did flot appear to
produce deleterlous effects in the Corwin’s study, the safety of iran
administration should be further investigated before a widespread utilization of
iron replacement in the ICU.
CONCLUSION
So far, six studies have described iron metabolism in critically iII patients. A
dectease in the availability of iran along with elevated ferritin levels are
generally observed. In these patients, iron metabolism is similar to that found in
inflammatory diseases and may contribute to the anemia obseried in ICU
patients. lron deficiency is difficult ta evaluate in the presence of inflammation.
Future studies using a novel approach based on hematologic indices would be
) useful [31]. Additional studies are necessary ta determine the utility of iran
supplementation alone in critically iii patients.
At the present time, thete is a lack of evidence ta support either oral or IV iron
administration in critically iII patients. Further studies are needed ta determine
the safety of iron supplementation in ICU patients, especially the link between
iron and clinical infectious risk. A large randomized study comparing IV iron, oral
iran and no iran supplement in rHuEPO-treated critically iII patients would be af
interest.
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Table 1:
ARTICLE III (Table 1): Studies describing iron metabolism in ICU patients
Studies Time of Iron [pmol/L] Ferritin Transf. Sat. Transferrin
measurement mean [pgIL] [¾] [g/L]
S mean mean mean
Reference Values with Inflammation [8,101
<9 30-200 10-20 <3
Surgical OU patients Week 1 4.1 652 12.8 1.7
[18]
Week2 4.1 1234 11.9 1.5
Week3 4.6 1536 13.4 1.4
Week4 6.9 1367 18.7 1.4
Medical bU patients Days 1-2 4.8a
471ab 16a 1.4ac
) 4days[3]
Days 6-8 6.Oa 767
a,b 15a
Days 13-15 6.5a 795a,b 22a 13
Days 20-25 8.la 77
4a,b 24a J4a.c
Days 31-40 7.Sa 723a,b 20a 1.5a
Medical & surgical ICU Day 2-3
4•9d 727b 16 NR
patients [19]
General ICU patients
[21]
FID Dayl NR 342 NR NR
No FID Day 1 NR 292 NR NR
I
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Multiple mechanical Day 1 9.5 832 NR 1
•7C
) trauma patients [20]
Day 2 3.9 547 NR
Day4 3.4 466 NR 15e
Day 6 4.0 530 NR
1.6e
Day 9 5.0 842 NR
FID, functional iron deficiency; OU, intensive care unit; NR, flot reported; Transf. Sat, transferrin
saturation; a median values; b Ferritin nglmL multiplied by 1 to convert to ferritin ugJL;
Transferrin mg/dL multiplied by 0.01 to convert to transferrin g/L;
d Iron ug/dL multiplied by
0.1791 to convertto iron umol/L
)
I
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?
inflammation
)
ARTICLE III (FIGURE 1): Decrease in iron recycling in the presence of
figure 1
tFERRITIN >30-200 gIL
tIRON STORAGE
LIRON MOBIUZATION
Iron metabolism in critically iii patients. Most of the iron available for erythropoiesis cornes from the
catabolism of senescent red blond ceils by the macrophages in the reticuloendothelial system. The
synthesis of ferritin is increased by IL-l and TNF. Hypoferremia rapidly sets in due to an increase in the
iron-binding capacity of ferritin to the detriment of transferrin. IL-l also stimulates lactoferrin synthesis.
Iron bound to lactoferrin is captured by the macrophages and stored in the form offenitin. Hepcidin could
be a centi-al mediator of iron sequestration in macrophages. Grey arrows: pathways increased by
inflammation; broken limes: pathways decreased by inflammation; IL-1, interleukin-1; IL-6,
interleuldn-6; RBC, red blood cel]s; TNF, tumour necrosis factor; TR&NSFERRIN SAT,
transferrin saturation.
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ARTICLE IV : Epoetin Alfa combined with a restrictive transfusion
approach in critically iii patients is 40 000 units once weekly the optimal
dosage?
INTRODUCTION
Anemia is a frequent complication in intensive cate unit (ICU) patients. This
multifactorial anemia sets in quickly and increases the use of blood transfusion
in critically iii patients. In recent years, clinicians became aware of the
importance of limiting blood transfusion. Traditionally, the administration of red
blood celI units to critically iII patients has been a common practice in order to
maintain hemoglobin concentrations above 100 g!L.1 The Transfusion
Requirement in Critical Care (TRICC) trial demonstrated that this approach does
not offer any advantages over a restrictive transfusion approach and, for some
patients, may even be harmful.2 However, blood transfusion is stili common in
lCUs. Recently, the Anemia and Blood Transfusion in Critical Care (ABC)
) investigators reported that 37% of ICU patients in western Europe were
transfused and that close to 70% of these patients received a transfusion within
48 hours of their admission to the ICU.3 Also, a prolonged ICU Iength of stay leU
to a constant need for transfusion.3 The CRIT study conducted in the United
States showed similar results.4
The administration of recombinant human erythropoietin (EPO) is one of the
strategies proposed to decrease the need for transfusions in critically iII patients.
An important study conducted by Corwin et al. in 2002 showed that
administering 40 000 units of EPO once weekly reduced the number of
transfused patients by 10% and teduced overall transfusion needs by 19%,
compared with placebo.5 The resuits of this study are interesting for a blood
conservation program but offer no clinical benefits. Moreover, it is not known
whether a similar reduction in the need for transfusion could have been
achieved simply by using a transfusion threshold of 70 gIL, without having to
) administer EPO.6 It has not been demonstrated that EPO ptovides additional
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benefits to a restrictive transfusion approach in terms of either clinical outcome
or the conservation of blood supplies. Consequently, in the absence of a
restrictive transfusion approach such as the one proposed in the TRICC trial,
the administration of EPO in ICU does flot appear to be optimal or judicious.2
The effect of EPO should be maximized during hospitalization in the ICU, where
there is a greater need for transfusion. No pharmacodynamic studies evaluating
different EPO regimens are available. Based on the current data in the
literature, it is not possible to conclude whether an optimal effect is achieved
during the ICU stay with a once-weekly EPO dose of 40 000 units.
Our hypothesis was that a dose of EPO > 40 000 units per week could provide
higher reticulocyte count and higher hemoglobin concentrations in ICU patients.
We designed a study to determine whether a dose of EPO > 40 000 units per
week, combined with a restrictive transfusion strategy, makes it possible to
) optimize erythropoiesis and hemoglobin concentrations specifically during the
ICU stay. Our study also measures variations in hemoglobin concentrations
when EPO is administered in the context of a restrictive transfusion approach.
METHODOLOGY
Objectives
The study was a prospective, open-label, multiple center trial. The primary
objective was to compare erythropoietic response to different doses of EPO
expressed as a mean variation in reticulocytes and hemoglobin during the ICU
stay, up to 28 days. When this study was elaborated, EPO use with critically iII
patients had flot been approved in Canada. Therefore, we also evaluated the
adverse events associated with EPO use.
Stttdy Population
This study was conducted in the surgical and medical ICU of three hospitals
providing specialized and ultraspecialized care in Quebec between July 2003
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and December 2004. The research protocol was apptoved by the ethics and
research committee at each of the hospitals. The criteria for inclusion were:
hospitalization in ICU > 72 hours, age > 18 years, APACHE Il score > 15,
hemoglobin < 110 gIL at time of inclusion and signed informed consent by the
patient or a family member. The criteria for exclusion were: known
hypersensitivity to epoetin alfa or human albumin, pregnancy or breast feeding,
hereditary hemoglobinopathy and coagulation disorders, active bleeding (30%
drop in hemoglobin or hematocrit in 24 hours or less), chronic dialyzed illness,
poorly controfled epilepsy over the previous 6 months or increased risk of
convulsions (head trauma, cerebrovascutar accident), cranial trauma,
autoimmune hemolysis (Coombs +), recent androgenic therapy and essential
thrombocytosis. Were also excluded patients unable to or not wanting to
receive transfusions, patients already on epoietin alfa or darbepoietin alfa,
patients with acute ischemic cardiac disease (myocardial infarction or unstable
angina) at the time of recruitment, patients who were expected to be discharged
) within 24 to 48 hours, patients with uncontrolled hypertension (systolic blood
pressure >200 ordiastolic blood pressure >110) afferadequate antihypertensive
therapy, acutely burned patients, patients with an admitting diagnosis of acute
gastrointestinal bleeding and subjects who had received phase Il experimental
drug or therapy within 30 days prior to this study. Patients receiving
experimental contrast agents were excluded if treated within 3 days prior to
study entry.
Treatmeut Fiai;
Patients included in the study received either 40 000 units of EPO (Ortho
Biotech, 40 000 units/mL) via subcutaneous injection once a week for a
maximum of 4 doses administered on days 1, 8, 15 and 22 during their ICU stay
(group A) or 40 000 units of EPO via subcutaneous injection twice a week for a
maximum of 4 doses administered on days 1,4, 8 and 12, during their ICU stay
(group B). EPO was discontinued upon discharge from ICU. EPO was
) Uiscontinued temporarily if hemoglobin > 125 g/L and resumed
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hemoglobin < 125 g/L to complete the missing doses. Patients were recruited
successively: the first 30 patients assigned to group A, the next patients to
group B. An independent safety committee determined whether the study could
be pursued after considering reports of adverse events in patients in group A.
AIl patients received 300 mg of ferrous sulfate supplement tid either oraHy or
via a nasogastric tube. In the event of gastric intolerance, the oral iron dose
could be decreased or discontinued, at the discretion of the physician.
Intravenous iron administration was not allowed. Patients receiving total
parenteral nutrition could, however, receive an iron supplement by intramuscular
injection.
I
The criteria for red blood celI transfusion were as follows: no transfusions based
solely on hemoglobin values. If the patient’s clinical condition required it fat the
physician’s discretion, for example : transient ischemic attack or dyspnea), a
) transfusion could be administered if hemoglobin < 70 g/L or if hemoglobin <90
g/L in the presence of acute myocardial infarction or unstable angina.
Basetin e Assessrn eut and Fottow-up
Demographic and diagnostic data were collected upon admission or at
recruitment into the study. The APACHE Il score was obtained within 24 to 48
hours of admission to ICU. Reticulocytes, hemoglobin and hematocrit were
monitored daily during the patient’s stay in ICU. Adverse events attributable ta
EPO were monitored daily from day 1 to day 28 of the study. Adverse events
attributable ta EPO were thromboembolic events (stroke, pulmonary embolism,
deep vein thrombosis), hypertension, seizures, thrombocytosis and pure red ceil
aplasia (PRCA) in the case of patients who developed a sudden loss of efficacy
or a sudden deterioration of their anemia. If PRCA was suspected and no cause
could be identified, antibody titers could be obtained. Baseline screening for
PRCA was performed prior to administration of the first dose of EPO and 30
days after the last dose. Blood samples were stored at -20°C, to be analyzed at
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a later time if this implication was suspected during the study. Hemoglobin and
hematocrit were measured 14 days and 30 days after the last dose of EPO to
monitor patients presenting with an exaggerated tesponse.
Statistical A natysis
This study was a pilot study and was not designed to have high power to detect
small differences. For financial and feasibility reasons, the ptesent study has
been designed to included 30 patients in each groups. BaseÏine characteristics:
Chi Square analysis was used for categorical data; analysis of variance fane
way ANOVA) was used for continuous variables. Frirnaiy end point: mean
) changes in reticulocytes and hemoglobin during the ICU stay fro
m baseline up
to day 28 were analyzed on group B versus group A with repeated-measure
analysis of variance. Safety: number of adverse events in group B versus group
A, from baseline up to day 28. Ail adverse events were evaluated in terms of
setiousness, causality and relatedness to study drug. Number of adverse events
) was analyzed with Fisher exact test on group B versus group A. Data are
expressed as mean ± SD. A two-sided alpha < 0.05 was considered statistically
significant.
RESU LIS
A total of 58 patients were included in the study with 30 patients in group A and
28 patients in group B. The baseline characteristics of the patients in both
groups were comparable (Table 1). The mean APACHE Il score was 21.3 in
group A and 21 .9 in group B (p=0.68). At the time of inclusion, close to half of
the patients were receiving a vasopressor, almost 90% cf the patients were
receiving an antibiotic, and approximately 73% of the patients in group A were
mechanically ventilated versus 96% in group B. The elevated ferritin and
decceased transferrin saturation levels obseR’ed in both groups were
characteristic of an inflammatory state.
)
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Primaiy Objectives
No statistically significant difference between the groups was obsenied in terms
of daily variation in reticulocytes during their ICU stay (Table 2). An important
increase in reticulocytes over baseline was observed in both groups.
Reticulocytes increased by a mean baseline value ot 51 ± 31 X 1091L to a
maximum 0f 191 ± 75 x 109/L on day 11 in group A. In group B, reticulocytes
increased from 65 ± 50 x 109/L to a maximum of 260 ± 70 x 109/L on day 21
(Figure 1). Mean hemoglobin during ICU stay was 91 ± 14 g/L in group A
compared with 86 ± 12 gIL in group B. No significant difference was observed
between the groups in terms of daily variation in hemoglobin concentrations
during ICU stay (Table 2 & Figure 2).
Adverse Events aitd Patient fottow-up
Six patients in group A died during the study compared with 8 deaths observed
in group B (p=0.55). Adverse events attributable to EPO are reported in Table 2.) Mean follow-up hemoglobin values 14 days after the final dose of EPO were
101 ± 17 gIL for group A compared with 95 ± 13 gIL for group B (p=0.24). Mean
hemoglobin values 30 days after the final dose were 105 ± 18 g/L compared
with 96 ± 13 g/L (groupAvs group B, respectively; p=0.11).
Transfusions dttriitg ICU stay
Mean pre-transfusion hemoglobin was 72 ± 9 g/L in group A and 67 ± 6 g/L in
group B. Sixty-seven percent (67%) of patients in group A did not receive a
transfusion compared with 46% in group B (p = 0.19). In ail, 20 units of red
blood cells were transfused during ICU stay to aIl of the patients in group A,
corresponding to 0.74 units per patient. Patients in group B received a total of
48 units of ted blood cells during their stay in ICU, corresponding to 1.7 units
per patient. No patient in group A and 1 patient in group B (2%) were transfused
with an hemoglobin > 90 g!L. In group A, pretransfusion hemoglobin
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concentrations exceeded 80 gIL in 4 cases (20%) compared with 2 cases (4%)
in group B.
Expositre to EPO and Iroit
EPO: over half (55%) of the patients in group A received only one dose of EPO;
17% received 2 doses; 10% received 3 doses; and 17% received 4 doses. Ail
patients in group B received at least 2 doses of EPO; 25% received 3 doses and
43% received 4 doses. On average, 80 000 units of EPO per patient were
administered in group A compared with 120 000 units per patient in group B.
This represents an exposure to EPO 1.5 times higher in group B. Iron : eighty
fine percent (89%) of the patients in group A received an oral iron supplement.
One patient did not receive an iron supplement and two patients received iron
by intramuscular injection. In group B, 96% of patients received oral iron and 1
patient did not receive iron.
) DISCUSSION
We assessed whether the administration of EPO at a dose > 40 000 units per
week leU to increased erythropoiesis stimulation during ICU stay. Our study
showed that there is no benefit to using a dose > 40 000 units per week. Prior to
our study, there were no data in the literature that would have made it possible
to determine the optimal EPO dose for ICU patients. A few studies, using
various dosages, have shown that EPO stimulates erythropoiesis in ICU
patients.79 Only two studies demonstrated that EPO administration reduced the
need for transfusions.5’1° In a previous study, Corwin et al. used a much higher
dose and demonstrated a decrease of close to 50% in the transfusion needs of
patients receiving EPO compared with placebo.1° In this study, the EPO doses
corresponded to 300 units/kg once a day for the first five days, then every two
days thereafter (approximately 100 000 units of EPO in ail during the first five
days, then approximately 60 000 units per week for a 70 kg patient).1° Based on
the more modest resufts of the second study by Corwin et aI.5, it became
) necessary to determine whethet an optimal effect s achieved with n EPO dose
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of 40 000 units once a week. A pharmacodynamic study was required before
planning s larger trial with clinical outcome such as end-organ morbidity or
mortality.
Although there was no statistically significant difference between the two groups
in terms of reticulocyte change during ICU stay, it is interesting to note that a
trend toward an increase in the reticulocytes of patients in group B occured from
study day 14 to study day 21 compared with group A (FIGURE I and TABLE 2).
However, this observation is difficult to interpret given the small number of
patients in each group at the end of the study. The reticulocytes evolution
curves were much more similar from study day 1 to study day 14 (FIGURE I
and TABLE 2). Similar resuits were observed in a study using EPO 300 units/kg
every 2 days for 5 doses (corresponding to 20 000 units of EPO for 5 doses, for
a 70 kg patient) with intravenous iron.9 In this study, reticulocyte counts
increased from 56 ± 33 x 109/L to a maximum of 189 ± 97 x 109/L on day
J3•9 In
our study, the comparable reticulocyte variation in both groups shows that an
EPO dose > 40 000 units per week does not allow for s faster, higher or more
sustained response in ICU patients, with the possible exception of patients with
an ICU length of stay> 14 days. This observation is probably secondary to the
bone marrow’s Iimited ability to produce adequate erythropoiesis after high
doses of EPO have been administered.11 Consequently, bone marrow stores
may be replenished slowly after EPO is discontinued and may contribute to
prolonged anemia.’1
The anemia observed in critically iII patients is multifactorial.12 lnadequate
erythropoiesis secondary to inflammatory states contribute to this anemia.12 We
believe, therefore, that the patients most likely to benefit from EPO are those
who are severely iII, with multiple organ failure, and with prolonged ICU length of
stay. We tried to target this patient population by including patients with an
APACHE Il score > 15. Despite a mean APACHE li score around 21 in our
study, most patients had an ICU length cf stay < 2 weeks, thus leaving littie time
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to determine whether EPO had had a pronounced effect on hemoglobin
concentrations. No differences wete observed between the groups in terms of
the daily hemoglobin variation during ICU stay. There is no advantage to using a
dose of EPO > 40 000 units per week to optimize hemoglobin concentrations.
The transfusion thresholds were appropriately implemented in both groups. The
mean pretransfusion hemoglobin levels were 72 ± 9 g/L for patients in group A
and 67 ± 6 gIL for patients in group B. Despite that, more patients were
transfused in group B during the ICU period compared with group A. Patients in
group B received also more units of blood during their ICU stay. A
complementary analysis was performed to attempt to control for the difference
in the transfusion rates and the number cf units transfused between the groups
(FIGURE 3). Nontransfused patients (FIGURE 3a) and transfused patients
(FIGURE 3b) were analysed separately in both groups. When controlling for the
transfusion rates, the daily variation in hemoglobin between the two groups
du ring their ICU stay was similar.
)
In the TRICC trial, Hébert et al. showed that maintaining hemoglobin between
70 and 90 gIL by transfusing when hemoglobin <70 gIL, was just as effective as
a target hemoglobin level cf between 100 and 120 gIL with a transfusion given
when hemoglobin < 100 g/L.2 Moreover, with a restrictive transfusion approach,
the mortality rate was lower in less critically iII patients and patients < 55 years.2
There is also no evidence that a liberal transfusion approach can decrease the
duration of mechanical ventilation.13 Only patients with unstable angina or acute
myocardial infarction might possibly benefit from a higher transfusion
threshold.’4 Tissular oxygen consumption following red blood ceIl transfusion
does not appear to increase as expected.15’16 Consequently, ted blood ceil
transfusion would not make it possible to achieve clinical benefits that were as
significant as anticipated. Moreover, critically iII patients may be more sensitive
to transfusion-related complications such as infection17, pulmonary edema7,
and the formation of microthrombosis.16 In light of these observations, blood
conservation measures must be introduced in ICUs in order to avoid
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unnecessary transfusions and conserve blood supplies. Limiting Iaboratory
analyses and decteasing the volume of collection tubes are among the
proposed strategies.3 The introduction of a restrictive transfusion protocol,
based on the patient’s clinical condition rather than on a single hemoglobin
value is an important step to implement a blood conservation strategy in
critically III patients. It has been shown that EPO makes it possible to reduce the
need for transfusion in ICU patients, but no clinical benefit has been
demonstrated.5 EPO is an expensive drug. In contrast, a restrictive transfusion
approach is inexpensive and improved clinical outcomes.2 The use of EPO
without a restrictive transfusion approach would not be efficient. We believe
that, in order ta be efficient, EPO use in this context must provide additional
clinical benefits.
Our study is the first ta evaluate the effect of EPO in combination with a
restrictive transfusion approach as used in the TRICC trial.2 The mean pre
transfusion hemoglobin value observed in the Corwin et al. study was 86 gIL.5
Our more restrictive transfusion criteria made it possible to achieve mean
hemoglobin pre-transfusion values of 72 gIL for group A and 6f glL for group B.
More than haif of the patients in group A and nearly 50% af the patients in group
B did not receive any transfusions. lnterestingly, despite a mean transfusion
threshold of 72 gIL, the overali mean hemoglobin for patients in group A was 91
gIL during their stay in ICU. Generally, a constant decline in hemoglobin of
approximately 2 g!L per day is observed in critically iII patients.18 In our study,
we saw a stabilization of hemoglobin concentrations close to 90 gIL for 28 days.
The ABC study reported that the hemoglobin concentrations of ail ICU patients
converged at around 100 ta 110 gIL, for a mean transfusion threshold of 84
g!L.3 Our study shows that 40 000 units per week of EPO mai ntain hemoglobin
levels around 90 g/L when used with more restrictive transfusion thresholds.
The decrease in iran availability seen in inflammatory states may contribute ta
inadequate response ta EPO in ICU patients.19 Thus, EPO must be used with
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iran supplementation to optimize the erythropoietic response. However, the
route of choice in that context remains ta be determined.’9 Given the
hemodynamic adverse effects that are possible with certain formulations of
intravenous iran and the risk af infection, the patients in our study received an
oral iran supplement. Futures studies comparing intravenous iran
supplementation with oral iron in EPO-treated critically III patients are needed.
Dur study was not designed ta evaluate the safety of EPO use in critically iII
patients. However, given the limited experience with EPO use in ICU, a safety
monitoring was requited. Twa larger trials reported that EPO did not increase
adverse events campared ta placebo. 5,10 In aur study, EPO was temporarily
discontinued if hemoglobin concentration increased over 125 gIL in arder ta
reduce the risk of thromboembolic events.
The major limitation ta this study is prabably our small sample size. This study
was designed ta explore the erythropaietic respanse during ICU stay. The
number of patients decreased pragressively during ICU stay, leaving few
patients for the analysis over 14 days. Changes in reticulocyte count in 2 weeks
may simply reflect output of shift reticulocytes and not true expansion of
erythropoiesis.2° Hawever, the pharmacadynamic profiles of the 2 groups were
similar, reflecting the same trend of response.
CONCLUSION
EPO at a dose greater than 40 000 units per week does not result in faster,
higher or more sustained stimulation af reticulocytes or hemoglobin production
in ICU patients.
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ARTICLE IV (Table 1): Baseline characteristics
Group A Group B p
(n30) (n 28) value
mean (SD), years 65.5 (13.1) 63.0 (13.7) 0.48
Sex, No. (¾)
Men 18 (60) 21(75) 0.27
APACHE II score, mean (SD) 21 .3 (4.4) 21 .9 (5.7) 0.68
MODS at enroilment, mean (SD) 6.1 (3.6) 6.3 (3.2) 0.82
Primary diagnosis ‘, No. (¾)
Pneumonia 7 (23) 8 (29)
Respiratory 4 (13) 5 (18)
Sepsis 7 (23) 6 (21)
Post-operative 11(37) 6 (21)
Neurologic 1 (3) 0
Trauma 0 2 (7)
Cardiovascular 0 1 (4)
History of coronary disease, No. (%) 5 (17) 4 (14) 1.00
Mechanical ventilation, No. (%) 22 (73) 27 (96) 0.03
Drugs at study day 1, No. (%)
Any vasopressort 15 (50) 13 (46) 1 .00
Drotrecogin alfa 3(10) 3(11) 1.00
Any antibiotic 28 (93) 25 (89) 0.67
Baseline laboratory values, mean (SD)
Hemoglobin, gIL 89(11) 82(13) 0.04
Hematocrit, % 26.7 (4,1) 24.5 (4.0) 0.05
Reticulocytes, x 109/L 51(31) 65 (50) 0.22
Ferritin, ug/L 821 (641) 921 (1066) 0.68
Transferrin saturation, % 19.7 (14.0) 14.7 (9.4) 0.25
Folates, nmol/L 19.4 (13.3) 18.3 (11.3) 0.75
Vitamin B12, pmol/L 713 (491) 588 (520) 0.36
> 0,05; tdopamine, dobutamine, epinephrine, norepinephrine, vasopressin; APACHE: Acute
Physiology And Chronic Health Evaluation; MODS: Multiple Organ Dysfunction Syndrome
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ARTICLE IV (Table 2): Erythropoiesis parameters during ICU stay
Group A Group B p value
(n=30) (n=28)
Reticulocytes, mean (SD)
study day
1 51(31) 65 (50) 0.22
7 129 (83) 141 (82) 0.68
14 167(61) 164 (75) 0.95
21 148 (66) 260 (70) 0.06
Hemoglobin, mean (SD)
study day
1 89(11) 82(13) 0.04
7 91(15) 87 (13) 0.34
14 93(15) 87(11) 0.34
21 90(14) 84(14) 0.52
28 86 (13) 79 (17) 0.67
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ARTICLE IV (Table 3) : Adverse events possibly attributable to EPO
Groupe A Groupe B p value
(n=30) (n= 28)
Deep vein thrombosis or pulmonary embolism 0 2 NS
Stroke 1 0 NS
Seizures O O NS
Hypertension 2 0 NS
Thrombocytosis 0 1 NS
Suspected PRCA O O NS
NS: flot statistically significant; PRCA : pure red ce!! aplasia
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ARTICLE IV (Figure 1) Reticulocytes count during intensive care
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ARTICLE IV (Figure 2): Course of hemoglobin concentration during
intensive care
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ARTICLE IV (Figure 3a) . Course of hemoglobin during intensive care:
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ARTICLE IV (Figure 3b) : Course of hemoglobin during intensive care:
transfused patients
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